Global Infectious Diseases Partnering 2014-2020: Deal trends, players and financials
Global Infectious Diseases Partnering 2014-2020: Deal trends, players and financials report provides comprehensive understanding and unprecedented access to the infectious partnering deals and agreements entered into by the worlds leading healthcare companies.
Global Infectious Diseases Partnering 2014 to 2020 provides the full collection of Infectious Diseases disease deals signed between the world’s pharmaceutical and biotechnology companies since 2014.
- Trends in Infectious Diseases partnering deals
- Financial deal terms for headline, upfront and royalty by stage of development
- Infectious Diseases partnering agreement structure
- Infectious Diseases partnering contract documents
- Top Infectious Diseases deals by value
- Most active Infectious Diseases dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive Infectious Diseases disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Infectious Diseases deals.
The report presents financial deal terms values for Infectious Diseases deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of Infectious Diseases dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in Infectious Diseases dealmaking since 2014 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading Infectious Diseases deals since 2014. Deals are listed by headline value. The chapter includes the top 25 most active Infectious Diseases dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to Infectious Diseases deals since 2014 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all Infectious Diseases partnering deals by specific Infectious Diseases target announced since 2014. The chapter is organized by specific Infectious Diseases therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all Infectious Diseases partnering deals signed and announced since 2014. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Infectious Diseases partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Infectious Diseases technologies and products.
Global Infectious Diseases Partnering 2014 to 2020 is intended to provide the reader with an in-depth understanding and access to Infectious Diseases trends and structure of deals entered into by leading companies worldwide.
Global Infectious Diseases Partnering 2014 to 2020 includes:
- Trends in Infectious Diseases dealmaking in the biopharma industry since 2014
- Analysis of Infectious Diseases deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of Infectious Diseases deal contract documents
- Comprehensive access to over 1500 Infectious Diseases deal records
- The leading Infectious Diseases deals by value since 2014
- Most active Infectious Diseases dealmakers since 2014
The report includes deals for the following indications:
Bacterial: Anthrax, Campylobacter Jejuni, Clostridium difficile, Diphtheria, Escherichia Coli (E-coli), Group A Streptococcus, Group B Streptococcus, Haemophilus influenzae type b (Hib), Helicobacter Pylori, Lyme disease, Methicillin-resistant Staphylococcus aureus (MRSA), Mycobacterium avium, Pertussis (Whooping Cough), Pseudomonas aeruginosa, Salmonella, Sepsis, Tetanus, Tuberculosis (TB), plus other bacterial indications
Viral: Common cold, Cytomegalovirus, Ebola, FIV, Foot and mouth disease, Hepatitis A, B, C, D, Herpes simplex, HIV, Influenza, H5N1 (Avian Flu), H1N1 (Swine Flu), Japanese encephalitis, Polio, Respiratory syncytial virus (RSV), Zika, plus other viral indications.
Fungal: Nail Psoriasis, Onychomycosis (Nail infection), plus other fungal indications
Tropical: African trypanosomiasis (Sleeping sickness), Dengue fever, Malaria, West Nile Virus, Yellow fever, plus other tropical indications
In Global Infectious Diseases Partnering 2014 to 2020, available deals and contracts are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Infectious Diseases Partnering 2014-2020 report provides comprehensive access to available deals and contract documents for over 1,500 infectious diseases deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are the sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Infectious Diseases Partnering 2014 to 2020 provides the reader with the following key benefits:
- In-depth understanding of Infectious Diseases deal trends since 2014
- Access Infectious Diseases deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Infectious Diseases partner companies
- Comprehensive access to over 1500 links to actual Infectious Diseases deals entered into by the world’s biopharma companies
- Indepth review of Infectious Diseases deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Infectious Diseases opportunities
- Uncover companies actively partnering Infectious Diseases opportunities
Chapter 1 – Introduction
Chapter 2 – Trends in Infectious Diseases dealmaking
2.2. Infectious Diseases partnering over the years
2.3. Infectious Diseases partnering by deal type
2.4. Infectious Diseases partnering by industry sector
2.5. Infectious Diseases partnering by stage of development
2.6. Infectious Diseases partnering by technology type
2.7. Infectious Diseases partnering by therapeutic indication
Chapter 3 –Financial deal terms for Infectious Diseases partnering
3.2. Disclosed financials terms for Infectious Diseases partnering
3.3. Infectious Diseases partnering headline values
3.4. Infectious Diseases deal upfront payments
3.5. Infectious Diseases deal milestone payments
3.6. Infectious Diseases royalty rates
Chapter 4 – Leading Infectious Diseases deals and dealmakers
4.2. Most active in Infectious Diseases partnering
4.3. List of most active dealmakers in Infectious Diseases
4.4. Top Infectious Diseases deals by value
Chapter 5 – Infectious Diseases contract document directory
5.2. Infectious Diseases partnering deals where contract document available
Chapter 6 – Infectious Diseases dealmaking by therapeutic target
6.2. Deals by Infectious Diseases therapeutic target
Appendix 1 – Directory of Infectious Diseases deals by company A-Z since 2014
Appendix 2 – Directory of Infectious Diseases deals by deal type since 2014
Appendix 3 – Directory of Infectious Diseases deals by stage of development since 2014
Appendix 4 – Directory of Infectious Diseases deals by technology type sinc 2014
Further reading on dealmaking
Deal type definitions
About Wildwood Ventures
Recent report titles from CurrentPartnering
Table of figures
Figure 1: Infectious Diseases partnering since 2014
Figure 2: Infectious Diseases partnering by deal type since 2014
Figure 3: Infectious Diseases partnering by industry sector since 2014
Figure 4: Infectious Diseases partnering by stage of development since 2014
Figure 5: Infectious Diseases partnering by technology type since 2014
Figure 6: Infectious Diseases partnering by indication since 2014
Figure 7: Infectious Diseases deals with a headline value
Figure 8: Infectious Diseases deals with upfront payment values
Figure 9: Infectious Diseases deals with milestone payment
Figure 10: Infectious Diseases deals with royalty rates
Figure 11: Active Infectious Diseases dealmaking activity since 2014
Figure 12: Top Infectious Diseases deals by value since 2014
- $3,495: single-user
- $5,245: multi-user
- $10,485: single site license
- $17,475: global site license
A full explanation of license type definitions can be found here.
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
All card payments are processed by SagePay.
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
2A, 3D BioMed, 3M, 3rd People’s Hospital of Shenzhen, 3SBio, 4SC Discovery, 10X Genomics, 36 Strategies General Trading, A*STAR Agency for Science, Technology and Research, A*STAR Institute of Microelectronics (IME), A*STAR Singapore Immunology Network, A*STAR’ Institute of Molecular and Cell Biology, A-Alpha Bio, Aarhus University Hospital, AB Analitica, Abbott Laboratories, Abbvie, AbCellera, Abeome, ABIVAX, Ablexis, Academic Medical Center, Academy of Military Medical Sciences (China), Accelerated Enrollment Solutions, Accelerate Diagnostics, Access BIO, Acelrx Pharmaceuticals, Achaogen, Achillion Pharmaceuticals, Actelion, Actinium Pharmaceuticals, Acumen Pharmaceuticals, Acurx Pharmaceuticals, Adaptive Biotechnologies, Adaptive Phage Therapeutics, Adimab, ADS, ADT Altona Diagnostic Technologies, Advaccine Biotechnology, Advanced Accelerator Applications, Advanced Biological Laboratories, Advanced BioNutrition, Advanced BioScience Laboratories, Aegea Biotechnologies, Aelix Therapeutics, Aeras, Aethlon Medical, Affinium Pharmaceuticals, Affinivax, Agenus Bio, Aglon, Agricultural Materials Company, Agricultural Research Service, AiCuris, AIDS Clinical Trials Group, AIDS Foundation of Chicago, AIMM Therapeutics, Aitbiotech, AIT Therapeutics, Akers Biosciences, Ako Med, Akonni Biosystems, Akorn, Alab, Alamo Pharma Services, Alaska Department of Health and Social Services, Albert Einstein College of Medicine, Aldevron, Alere, Algenex, Algernon Pharmaceuticals, Alibaba Health, Allergan, Allergan (name changed from Actavis), AlloVir, Alnylam Pharmaceuticals, Alphamab Biopharmaceuticals, Alpha Tech Pet, Altan Pharma, Altimmune, Alverno Clinical Laboratories, Alvogen, Al Zahrawi Medical Supplies, Amarex Clinical Research, A Menarini Diagnostics, American Foundation for AIDS Research (amfAR), American Gene Technologies, American Type Culture Collection (ATCC), Amerigen Pharmaceuticals, Ametek, Amgen, Amneal Pharmaceuticals, AmpliPhi Biosciences, Amplyx Pharmaceuticals, AMP Therapeutics, AMR, AN2 Therapeutics, Anacor Pharmaceuticals, Analog Devices, Anatara Lifesciences, Angelini Pharma, AnGes MG, ANI Pharmaceuticals, ANP Technologies, Ansell, Antabio, Antengene, Antigen Discovery, Antitope, AOP Orphan Pharmaceuticals, Aperiomics, Aphios, ApolloBio, Appili Therapeutics, Applied BioCode, Applied Biology, Applied DNA Sciences, Aptagen, Aptahem, Aptevo Therapeutics, Aptimmune Biologics, Aptorum Group, Aptuit, Aqua Pharmaceuticals, Aradigm, Aragen Bioscience, Aralez Pharmaceuticals, Arbutus, ArcDia, Arcturus Therapeutics, Ares Genetics, Ares Life Sciences, Argos Therapeutics, Aridis Pharmaceuticals, Arisan Therapeutics, Ark Animal Health, Ark Biosciences, Arno Therapeutics (inactive since 2017), Arrevus, Arrowhead Pharmaceuticals, Arrow Pharmaceuticals, Arsanis Biosciences, Artes Biotechnology, Artizan Biosciences, ARUP Laboratories, Asclepia Outsourcing Solutions, Ascletis, Aseptix, Asklepios Biopharmaceutical, Aspen Holding, Assertio Therapeutics, Astellas Pharma, Aston University, Astra Formedic, AstraZeneca, Atara Biotherapeutics, Atlangram, Atlas Genetics, Atnahs Pharma, Atomo Diagnostics, Atomwise, Atox Bio, Aurobindo Pharma, Auspherix, Australian Research Council, Autobio Diagnostics, AUT Roche Diagnostics Laboratory, AUT University, Avanzcare, Aviragen Therapeutics, Avivagen, Axela, Aytu BioScience, AzurRx BioPharma, Banco de Sangre de Servicios Mutuos, Baruch S Blumberg Institute, BASF, Basilea Pharmaceutica, Batavia Biosciences, BATM, Battelle, Bavarian Nordic, Baxter International, Bay Area Lyme Foundation, Bayer, Bayer CropScience, Bayer Healthcare, Baylor College, Baylor College of Medicine, Baylor Institute for Immunology Research, BB100, Beckman Coulter, Becton Dickinson, Beijing Clear Biotech, Beijing Genomics Institute (BGI), Beijing Keyuan Xinhai Pharma, Benitec Biopharma, BE Pharmaceuticals, Berg, Berlin Chemie, Beroni Group, Bestbion, Best Choice, Beth Israel Deaconess Medical Center, BGN Technologies, Bharat Biotech, BIA Separations, Bill and Melinda Gates Foundation, Bio-Manguinhos, Bio-Manguinhos/Fiocruz, Bio-Rad Laboratories, BIOASTER, BioCad Holding, Biocartis, BioClones, BioCryst Pharmaceuticals, bioCSL, Biodesix, Biodirection, Biofactura, Bio Farma, BioFire Diagnostics, Biofortis, BIOgenetiX, Bioharmony Therapeutics, Biohealth Innovation, Biohit, Biokinetic Europe, bioLytical Laboratories, Biomedical Advanced Research and Development Authority, Biomedical Catalyst Fund (UK), Biomerica, bioMerieux, Biomica, bioMONTR Labs, BiondVax, BioNeutral, BioNTech, BionX Medical Technologies, Biophage Pharma, BioPhausia, Biophore Pharmaceuticals, Bio Products Laboratory, BioReference Laboratories, BioReliance, BioSun Pharmed, Biosynex, Biota Pharmaceuticals, BioTecon Diagnostics, Biotest, Biothera, BioVersys, Blood Systems Research Institute, Bloom Burton, Bluejay Diagnostics, Blue Water Vaccines, BMG Pharmaceuticals, BMV Medica, Boehringer Ingelheim, Boehringer Ingelheim Vetmedica, Boragen, Boston Pharmaceuticals, Boulos and Cooper Pharmaceuticals, Bpifrance, Brahms, Brandeis University, BravoVax, Breathtec BioMedical, Breckenridge Pharmaceuticals, BridgeCrest Medical, Brigham and Women's Hospital, Brigham Young University, Brighton Biotech, Brii Biosciences, Brill Pharma, BRIM Biotechnology, Bristol-Myers Squibb, Broad Institute, Brown University, Bruker, Buoy Health, Burnet Institute, Butantan Institute, C3J Therapeutics, Cadila Pharmaceuticals, Caerus Discovery, Caliber Biotherapeutics, Calico, California Institute for Biomedical Research, California Institute for Medical Researc, California Institute for Regenerative Medicine, Calixar, Calliditas Therapeutics, Canadian Institutes of Health Research, Cancer Prevention and Research Institute of Texas, Candel Therapeutics, Cannabis Science, Canon U.S. Life Sciences, Cantab Anti-infectives, Cantel Medical (UK), CARB-X, Cardiome Pharma, Carestream Health, Carlina Technologies, Carpegen, Case Western Reserve University, CASI Pharmaceuticals, Caster Medical System, Catholic University Leuven, CDC Foundation, Cell Medica, Cell Therapy Catapult, Celularity, Cempra Pharmaceutical, Center for Genetic Engineering and Biotechnology (Cuba), Center for Human Genetics and Laboratory Medicine, Center for Infectious Disease Research, Center Point Clinical Services, Centers for Disease Control and Prevention, Centre for Drug Research and Development (CDRD), Centre National de la Recherche Scientifique, Cepheid, Cerus, Cevec Pharmaceuticals, Changchun BCHT Biotechnology, Chargeurs, Charite Universitatsmedizin Berlin, Charles River Laboratories, Chembio Diagnostics, ChemDiv, Chemipal, Children's Hospital Boston, Children's Hospital of Philadelphia, Chimerix, China Medical System, China National Biotech Group (CNBG), Chinese Academy of Sciences, Chinese Center for Disease Control and Prevention, Chiromics, Chroma Therapeutics, Chromocell, Chugai Pharmaceutical, Ciclofilin Pharmaceuticals, Cidara Therapeutics, Cigna Healthcare, Cilian, Cipher Pharmaceuticals, Cipla, Circassia, Citius Pharmaceuticals, CiToxLAB, City of Hope, City University of New York Center for Advanced Technology, Civica Rx, ClearPath, Clevexel Pharma, ClinicalRM, Clinigen, Clorox Company, Clover Biopharmaceuticals, CMC Biologics, CN Bio Innovations, CNS Pharmaceuticals, Co-Diagnostics, Coalition for Epidemic Preparedness Innovations, Cobra Biologics, Cocrystal Pharma, Codagenix, Colep, Columbia University, Colzyx, Conatus Pharmaceuticals, Concordia Pharmaceuticals, ContraFect, ContraVir Pharmaceuticals, COPAN, Copan Diagnostics, CoreBiome, Corgenix Medical, Corona Diagnostics, Correvio Pharma, Courtagen Life Sciences, Covance, Covar Pharmaceuticals, Create Vaccine Company, Cresset, Crestone Pharma, Critical Path Institute (C-Path), CROMA Pharma, Crown Laboratories, Crozet BioPharma, Crucell, CryoPort, CSL, CSL Behring, CSPC Pharmaceutical Group, Cubic, Cubist Pharmaceuticals, Cue Health, Cullinan Oncology, Cumberland Pharmaceuticals, Curetis, CureVac, CURx Pharmaceuticals, Cyclenium Pharma, Cyclica, Cyon Therapeutics, Cystic Fibrosis Foundation Therapeutics, Cystron Biotech, Cytodyn, CytoSorbents, Cytovance Biologics, d3 Medicine, Daiichi Sankyo, Daktari Diagnostics, Dalton Pharma Services, Dana-Farber Cancer Institute, DARA BioSciences, DASA, Dascena, DASH Analytics, DaVita Clinical Research, Da Volterra, DCN Diagnostics, Debiopharm, Decibel Therapeutics, DeciBio Consulting, deCODE Genetics, Defence Science and Technology Laboratory, Defense Advanced Research Projects Agency, Defense Threat Reduction Agency, Defyrus, Deinove, DelSiTech, Deltamune, Department of Defence, Department of Defense, Department of Health and Human Services, Department of Veterans Affairs, DesignMedix, Destiny Pharma, Devonian Health Group, Diagnomics, DiaSorin, Diassess, Diatherix, Diavax Biosciences, Diaxonhit, Dicerna Pharmaceuticals, Diffusion Pharmaceuticals, DigiPath Solutions, Discuva, Diversey Care, DNA Electronics, Domainex, Domain Therapeutics, DongKoo Bio & Pharma, Dorizoe Lifesciences, Dover Medical & Scientific Equipment, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Drugs for Neglected Diseases Initiative, Drukier Institute for Children's Health, Duke-NUS Graduate Medical School Singapore, Duke Clinical Research Institute (DCRI), Duke University, DuPont, Durata Therapeutics, Durect, Dyadic International, Dynavax Technologies, DynPort Vaccine Company, E25Bio, EastGate Biotech, Easton Pharmaceuticals, EB Pharma, Ecolab, Eddingpharm, Edelris, Edico Genome, Eiger BioPharmaceuticals, Eiken Chemical, EirGenix, Eisai, Eisai Inc, Eisai S.A.S, Elanco, ELC Group, Eli Lilly, Elton John AIDS Foundation, EluSys Therapeutics, Emcure Pharmaceuticals, Emerald Organic Growth, Emergent BioSolutions, Emergex Vaccines, Emmes, EMM Life Science, Emory University, Enable Biosciences, Enamine, EnBiotix, Endo International, Enesi Pharma, Engility, Enigma Diagnostics, Enlivex, Enochian Biosciences, Entasis Therapeutics, Enterome Bioscience, Enumeral Biomedical, EnvisionRx, ENYO Pharma, Enzymatica, Epivax, Ethicon Endo-Surgery, Ethos Veterinary Health, Ethris, Etna Biotech, Etubics, Euprotec, Eureka Eurostars, Eurobio, EuroClone, Eurofarma, European Commission, EUSA Pharma, Evaxion Biotech, Everest Medicines, EverlyWell, Evogene, Evolva, Evotec, EVQLV, Excision BioTherapeutics, Excivion, ExeGi Pharma, ExoStat Medical, Expedeon, Express Scripts, ExThera Medical, Eyevance, F2G, Fagron, Fair Access Medicines, Fannin, Farmacore Biotechnology, Fast-Track Diagnostics, Fatro, Federal Ministry of Education and Research (BMBF), Fedora Pharmaceuticals, Feinstein Institute for Medical Research, Ferring Pharmaceuticals, Fina Biosolutions, Finch Therapeutics, Finlay Institute, Finorga, Fio, Fisher Healthcare, Five Prime Therapeutics, Fleming Fund, Flemish agency for Innovation by Science and Technology, Florida State University, Flow Pharma, FluGen, Fluidigm, FOB Synthesis, Folia Biotech, Food and Drug Administration (FDA), Forge Therapeutics, Fortive, Fortress Biotech, Fosun Pharmaceutical, Foundation for Biomedical Research and Innovation, Foundation for Innovative New Diagnostics, Fraunhofer Institute for Toxicology and Experimental Medicine ITEM, Frederick National Laboratory For Cancer Research, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Frontier Biotech, FSC Laboratories, Fujifilm, Fujifilm Diosynth Biotechnologies, Fujifilm Pharma, Fundacion Medina, G-Tech Bio, Galapagos, Galmed Pharmaceuticals, Garmatex Technologies, GB Pharma Holdings, GC Pharma, Gedeon Richter, GE Healthcare, Gen-Probe, GEn1E Lifesciences, Genentech, GeneOne Life Science, GenePOC, General Motors, Generation Biotech, Generex Biotechnology, GeneThera, Genetic Immunity, Geneva Foundation, Genexine, Genexo, Genmab, Genocea Biosciences, Genome Canada, Genome Institute of Singapore, GenTegra, Genticel, GenVec, Geom Therapeutics, George Mason University, Georgia State University Research Foundation (GSURF), GeoVax, German Cancer Research Center, Gibraltar Brothers and Associates, Gilead Sciences, GlaxoSmithKline, GlaxoSmithKline Biologicals, Glenmark Pharmaceuticals, Glide Technologies, Global Antibiotic Research and Development Partnership, Global Dx, Global Good Fund, Global Health Innovative Technology Fund (GHIT), Globavir Biosciences, GNA Biosolutions, Goffin Molecular Technologies, Google, Government of Australia, Government of Canada, Grameen Health, Great Basin Scientific, Green Cross LabCell, Greenlight Biosciences, Griffith University, Grifols, Gritstone Oncology, Group K Diagnostics, Guangzhou Institute of Respiratory Disease, Guilin Pharmaceutical, GVK Biosciences, H&P Labs, Hackensack Meridian Health, Hadasit Medical Research Services and Development, Hainan Savy Akers Biosciences, Hainan Savy Investment Management, Hainan Sihuan Pharmaceutical, Haisco Pharmaceutical, Halfpenny Technologies, HaloVax, Halozyme Therapeutics, Halyard Health, Hamilton Company, Hampton University, Hancom Group, Hannover Medical School, Harbour Biomed, Harvard Medical School, Harvard University, Hatchtech, Hawaii Biotech, HEALTH Biomed, Healthcare Royalty Partners, Health Decisions, HealthTrust, HealthTrust Purchasing Group, Health Vector, Heat Biologics, HEC Pharm, Helix2, HelixBind, Helix BioPharma, Helmholtz Centre for Infection Research, Helperby Therapeutics, HemispheRx Biopharma, Henry M. Jackson Foundation, Henry Schein, Hepatitis B Foundation, Hetero Labs, Heumann Pharma Generics, Hi-Tech Pharmacal, HiberGene Diagnostics, Hikma Pharmaceuticals, HitGen, HIV Interactions in Viral Evolution (HIVE) Center, HIV Resistance Response Database Initiative, Hoffmann La Roche, Hologic, Hong Kong Polytechnic University, Hookipa Pharma, Horizon 2020, Horizon Discovery, Hospices Civils de Lyon, Hoth Therapeutics, Howard Hughes Medical Institute (HHMI), HP, Hsiri Therapeutics, HSRx Group, HTC ChemRar, Hudson Robotics, Hugel, Humabs BioMed, Human Vaccines Project, hVIVO, HyGreen, iBio, IBT Bioservices, Icahn School of Medicine at Mount Sinai, ICB Pharma, Ichor Biologics, Ichor Medical Systems, IDbyDNA, ID Genomics, IDT Biologika, iFLYTEK, IGXBio, IHI, ILiAD Biotechnologies, Illumina, ILUM Health Solutions, ImageIQ, ImmBio, Immune Design, Immune Targeting Systems, Immune Therapeutics, Immunexpress, Immuno Diagnostic, ImmunoQure, Immunotech Laboratories, Immunovaccine, Immuron, Impax Laboratories, Imperial College London, Imutex, IncellDx, InDevR, Indiana University, Indian Council of Medical Research, Infectious Disease Research Institute (IDRI), Inflammatix, Ingenza, Inhibitor Therapeutics, InnaVirVax, Innosuisse, Innovare, Innovasource, Innovate UK, Innovation Pharmaceuticals, Innovation Skane, Innovative Medicines Initiative (IMI), Innovo, Inotrem, iNova Pharmaceuticals, Inovio, Inovio Pharmaceuticals, Inphilco, Inserm, Inserm Transfert, Insmed Inc, Inspyr Therapeutics, InstantLabs, Institute for Bioscience and Biotechnology Research, Institute for Systems Biology, Institute of Biomedical Research, Institute of Materia Medica, Instituto Mato-grossense do Algodão, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intarcia Therapeutics, IntegraGen, Integral Molecular, Integrated BioTherapeutics, Integrated DNA Technologies, Intel, Intelligence Advanced Research Projects Activity (IARPA), Intent Solutions, Interlab INTERAUTOMATIKA UAB, International AIDS Vaccine Initiative, International Association of Providers of AIDS Care, International Consortium on Anti-Virals, International Medica Foundation, International Partnership for Microbicides, International Vaccine Institute (IVI), Interpace Diagnostics Group, Intralytix, Intravacc, iNtRON Biotechnology, Ippox Foundation, Ipsen, Isagro, IsoPlexis, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Israel Investment Center, Italfarmaco, Jade Therapeutics, Jai Capital, JAJ International, Janssen Biotech, Janssen Diagnostics, Janssen Pharmaceuticals, Janssen Pharmaceutica NV, Janssen Research & Development, Janssen Therapeutics, Janssen Therapeutics EMEA, Japan Tobacco, Jazz Pharmaceuticals, J Craig Venter Institute, Jenner Institute, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Egens Biotechnology, Jiangsu Hengrui Medicine, Johns Hopkins Medicine (JHM), Johns Hopkins University, Johnson & Johnson, Johnson & Johnson Innovation, JSC Pharmadis, JSR, Junshi Biosciences, KAI Research, KaloBios Pharmaceuticals, Kalon Biotherapeutics, Kalos Therapeutics, Kansas City Area Life Sciences Institute, Kansas State University, Karius, Karolinska Institute, Kemin Industries, Kim & Friends, Kimberly-Clark, Kineta, King's College Hospital, King Saud University, Kleo Pharmaceuticals, Knight Therapeutics, KNOW Bio, Kurabo, Kurve Technology, Kymab, Kyorin Pharmaceutical, Laboratorios Liomont, Laboratory of Malaria Immunology and Vaccinology (LMIV), Lachlan Pharma, La Jolla Institute for Allergy & Immunology, La Jolla Pharmaceutical, Lakewood-Amedex, LALREAN, LamdaGen, Lannett, LatAm Clinical Trials, Laurus Labs, Lawson Health Research Institute, Lead Discovery Center, Leaf Biopharmaceutical, LegoChem Biosciences, Lehigh University, Leibniz-Institut fur Molekulare Pharmakologie, Leicester University, Leiden University, Leidos, Lenovo, Leonard-Meron Biosciences, LEO Pharma, Leukocare, LexaGene, LFB Group, LGC, Libbs Farmaceutica, LifeArc, Ligand Pharmaceuticals, Li Ka Shing Foundation, Liverpool School of Tropical Medicine, Livzon Mabpharm, Locus Biosciences, Lonza, Los Angeles Biomedical Research Institute, Louisiana State University, Lucideon, Luminex, LumiraDx, Lumos Pharma, Lund University, Lyndra Therapeutics, Lysando, Lytica Therapeutics, MaaT Pharma, mAbXience, Macrogenics, Macrolide Pharma, Makerere University, Mallinckrodt Pharmaceuticals, Mammoth Biosciences, Mapp Biopharmaceutical, Mark Zuckerberg, Marrone Bio Innovations, Maryland Technology Development Corporation, Massachusetts General Hospital, Massachusetts Institute of Technology, MassBiologics, Mateon Therapeutics, Matinas Biopharma, Matrivax, Maxor National Pharmacy, Mayo Clinic, Mayo Clinical Ventures, MBio Diagnostics, McKesson, MEDCIS Pathlabs, Medgenics, Medicago, Medicinal Genomics, Medicines360, Medicines for Malaria Venture, Medicines Patent Pool Foundation, Medigen Biotechnology, MediGene, MedImmune, MedinCell, Mediphos, Medisur, Medivir, Medizone International, Medline Industries, MedMira, Meiji Seika, Melinta Therapeutics, Memo Therapeutics, Menarini, Menzer, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Meridian Bioscience, Meridian IT, Meridian Life Science, Meridian Medical Technologies, MerLion, Mesa Laboratories, Metabiota, Mexican National Technology and Science Council, MGB Biopharma, MGI Pharma, MicrobeDx, Microbion, Microbiotix, Microbix Biosystems, Micro Imaging Technology, Microsoft, MicuRx Pharmaceuticals, Midatech, Mikrogen, Milenia Labs, MilliporeSigma, MinervaX, Ministry of Finance (China), Ministry of Industry and Information Technology, MiniVax, Miriam Hospital, Mission Pharmacal, MMS, Moberg Pharma, Mobidiag, MockV Solutions, Moderna Therapeutics, Molbio Diagnostics, Moleculin Biotech, Molnlycke Health Care, Mologen, Mologic, Monash University, Montefiore Health System, Montreal Heart Institute, Motic, Motif Bio, Mount Sinai Health System, MRIGlobal, MSD, MSD Wellcome Trust Hilleman Laboratories, MSN Laboratories, Mucosis, Mundipharma, Mundo Sano, MWMedical, My Brother’s Keeper, Mycoses Study Group Education & Research Consortium, Mycovia Pharmaceuticals, Mylan Laboratories, Mylan Pharmaceuticals, MyLife Technologies, Mymetics, Myriad RBM, N1 Technologies, Nabriva Therapeutics, NacuGen Therapeutics, NanoBio, NanoLock, NanoMosaic, NanoPass Technologies, NanoPin Technologies, Nanosphere, Nanotherapeutics, NanoViricides, Napo Pharmaceuticals, National Cancer Institute, National Center for Foreign Animal and Zoonotic Disease Defense, National Development and Reform Commission, National Disease Research Interchange, National Health and Family Planning Commission, National Healthcare Services (NHS), National Health Service, National Heart, Lung and Blood Institute, National Immunobiological Company, National Institute for Communicable Disease Control and Prevention (China), National Institute for Public Health and the Environment, National Institute for Viral Sidease Control and Prevention, National Institute of Allergy and Infectious Diseases, National Institute of Biomedical Innovation, National Institute of Cholera and Enteric Diseases, National Institute of Dental and Craniofacial Research (NIDCR), National Institute of General Medical Sciences, National Institute of Hygiene and Epidemiology, National Institute of Mental Health, National Institute of Standards and Technology, National Institute of Vaccines and Medical Biologicals, National Institute on Drug Abuse (NIDA), National Institutes of Health, National Kidney Registry, National Research Council Canada, National Research Council Industrial Research Assistance Program, National Research Council of Canada, National Science Foundation, Nationwide Laboratory Services, Naval Medical Logistics Command, Naval Medical Research Center, Navy Medical Research Centre, Near Patient Diagnostics, Nestle Health Science, Neurimmune Therapeutics, NeuroVive Pharmaceutical, Nevakar, Newsummit Biopharma, New York Blood Center, New York City Health and Hospital, New York Medical College, New York State Department of Health, New York University, Next Gen Diagnostics, Nicklaus Children’s Hospital, Nimbus Therapeutics, Nipro Corporation, NitricGen, NMI Natural and Medical Sciences Institute, Noble Biomaterials, Noble Life Sciences, Norgine, Northern Michigan University, Noscendo, Nosopharm, NovaDigm Therapeutics, Novaerus, Novan Therapeutics, Novartis, Novartis Institute for Tropical Diseases, Novasep, Novavax, Novel Anti-Infective Technologies, Novellus Biopharma, Novo, Novogene, Novotech, Novoteris, NOWDiagnostics, Nucorion, Nuevolution, Nutriband, Nuvo Pharmaceuticals, Nxstage Medical, Nyco Products Company, NYU Langone Medical Center, Oberland Capital, OBI Pharma, Octapharma, Ohio State University, Ology Bioservices, Oncologie, Oncology Pharma, OncoNano Medicine, OnCore Biopharma, Oncosynergy, One BioMed, Ontera, Onxeo, Opal Therapeutics, OpenBiome, OpGen, OPKO Health, Oppilotech, Optibrium, OraSure Technologies, Organic Vaccines, Oricula Therpeutics, Ortho-Clinical Diagnostics, OSEO, Osivax, Oswaldo Cruz Foundation (Fiocruz), Otonomy, Otsuka, Oxford Drug Design, Oxford Performance Materials, Oxitec, Oxygen Biotherapeutics, Pacific Biosciences, Pamlico Biopharma, Panacea Biotech, Paragon Bioservices, Paragon Genomics, ParaPRO, Paratek Pharmaceuticals, Partnership for Influenza Vaccine Introduction, Passport Food Safety Solutions, PATH (Appropriate Technology in Health), Patheon, PATH Malaria Vaccine Initiative, PathoFinder, PathogenDx, Paul G Allen Family Foundation, PaxGenBio, PaxVax, PCAS, Pcovery, PDS Biotechnology, Pebble Labs, Pediatric Praziquantel Consortium, Pennsylvania State University, PepTcell, Peptilogics, Perelman School of Medicine, Peripal, Periphagen Holdings, PerkinElmer, Pernix Therapeutics, Perrigo, Pevion, Pfenex, Pfizer, Phage Consultants, Phagelux, Pharco Pharma, PharmaJet, Pharma Scientific Research, PharmAthene, Pharmstandard, Phase Genomics, Phelix Therapeutics, Phico Therapeutics, Phylogica, PIC, Piedmont Pharmaceuticals, Pierre Fabre, Pinpoint Science, Plandai Biotechnology, Plant Response Biotech, Pluristem Therapeutics, PMV Pharma, PnuVax, Polyphor, Population Genetics Technologies, PositiveID, PPD, Pragma Pharmaceuticals, PreCheck, Precigen, Precision BioSciences, Predictive Technology Group, Premas Biotech, Premier Inc, Presidio Pharmaceuticals, Prestizia, Primetime Life Sciences, Primetime Medical Software, Princeton University, Prince William Science Accelerator, Probiomed, Procarta Biosystems, Productos Científicos, Profectus Biosciences, Profusa, Project Inform, Prokarium, Prokaryotics, Pro Med Diagnostics, Promiliad Biopharma, Prophase Labs, Protagen, Protein Sciences, Proteona, Provista Diagnostics, P T Lloyd Pharma, Public Health Agency of Canada, Public Health England, Public Health Vaccines, Pulmatrix, Purdue University, Pyrobett, Q-linea AB, Q2 Solutions, Qiagen, Qpex Biopharma, Qualtran, Qualyst Transporter Solutions, QuantumDx, Quaphaco, Quebec Government, Queensland Institute of Medical Research (QIMR), Quintiles, Quip Laboratories, R-Pharm, Rady Children's Institute for Genomic Medicine, Ragon Institute, Raiing Medical, Ranbaxy Laboratories, Rapid Micro Biosystems, Raptor Pharmaceutical, ReadCoor, Rebiotix, Recce Pharmaceuticals, Recida Therapeutics, Recipharm, Reckitt Benckiser, Redbiotec, RedHill Biopharma, Redx Pharma, Regeneron Pharmaceuticals, Regulus Therapeutics, Rempex Pharmaceuticals, Research Foundation to Cure AIDS, RetroVirox, Rheonix, Ridgeback Biotherapeutics, Rising Pharmaceuticals, RMX Biopharma, Roche, Roche Consumer Health, Roche Diagnostics, Rockefeller University, Roivant Sciences, Roka Bioscience, Romer Labs, Rougier Pharma, Royal Philips Electronics, R P Scherer, RSV, RTI International, Rutgers University, RVR Diagnostics, SAB Biotherapeutics, Sabin Vaccine Institute, SAB Therapeutics, Saint Louis University, Samsung Biologics, Samsung Electronics, Sanaria, Sandoz, Sanford Guide, Sangamo BioSciences, Sanofi, Sanofi-Pasteur, Saol Therapeutics, Saptalis Pharmaceuticals, Saromics, Sartorius, Sato Pharmaceutical, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), Savant HWP, SAW Diagnostics, Schrodinger, Science 37, Scienion, Scottish Enterprise, Scripps Research Institute, Scynexis, Searchlight Pharma, Seattle Biomed, Seattle Children's Hospital, Sedia Biosciences, Seegene, SEEK, Sekisui Diagnostics, Selecta Biosciences, Selectchemie, Selexis, SeLux Diagnostics, Sementis, Senova Systems, Sensocure, SeQuent Scientific, Seracare Life Sciences, Seraph Research Institute, SERB Pharmaceuticals, SerenaGroup, Seren Pharmaceuticals, Serenus Biotherapeutics, Seres Therapeutics, Serum Institute of India, Seventh Wave, Shanghai Desano Pharmaceutical, Shanxi Yabao Pharmaceutical Distribution, Shenzhen Arimab Biopharmaceuticals, Shenzhen China Resources Gosun Pharmaceutical, Shenzhen Hepalink Pharmaceutical, Sherlock Biosciences, Shijiazhuang Yuanmai Biotechnology, Shionogi, Shire Pharmaceuticals, Siemens, Siemens Healthineers, SIGA Technologies, Sight Diagnostics, Sigma-Tau, Sinapsis Medical Technologies, Sinergium Biotech, Singulex, Sino Biopharmaceutical, Sinotek-Advocates International Industry Development, Sinotherapeutics, Sinovac Biotech, Sinovant Sciences, SinSa Labs, SI Pharmaceuticals, Sirona Biochem, SK Chemicals, Small Business Innovation Research, SmartPharm Therapeutics, Soligenix, SomaGenics, SomaLogic, Somanetics, Sonoma Pharmaceuticals, Sophia Genetics, Sorrento Therapeutics, Sosei, South African Department of Health, Southern Research Institute, Southwest Research Institute, Spectral Medical, SpeeDx, Spero Therapeutics, Sphingotec, Splicos, Spotlight Innovation, Spring Bank Pharmaceuticals, SPR Therapeutics, SQI Diagnostics, SRI International, St. Jude Children's Research Hospital, STADA Arzneimittel, Stanford University, Stanford University School of Medicine, Starpharma, State of New Jersey, StatSure Diagnostic Systems, Stellar Biotechnologies, St Georges University of London, St Jude Medical, Stop TB Partnership, Strides Arcolab, Strides Polska, Strox Biopharmaceuticals, Summit Therapeutics, Sun Pharmaceutical, Sunstone Capital, SUNY Upstate Medical University, Surfacide, SutroVax, Suven Life Sciences, Suzhou NeuPharma, Swedish Bactiguard, Swedish Orphan Biovitrum, Swixx Biopharma, SymBio Pharmaceuticals, Symcel, Symphogen, Synairgen, Synthetic Biologics, Synthetic Genomics, Systec, SystemOne, T2 Biosystems, Tabuk Pharmaceutical, TaiGen Biotechnology, TaiMed, Taisho Pharmaceutical, Taiwan Liposome Company, Takeda Pharmaceutical, Takis Biotech, Talem Therapeutics, Talis Biomedical, Tangen Biosciences, TARGET PharmaSolutions, Taro Pharmaceuticals, Tauriga Sciences, TAXIS Pharmaceuticals, TB Alliance, TC BioPharm, Tecan, TechCare, Technical University of Denmark (DTU), Technion Research and Development Foundation, Technology Acceleration Partners, Technology Strategy Board (UK), TechnoVax, Tekmira Pharmaceuticals, Teligent, Temple University, Tencent Holdings, TeneoBio, TerraLink Horticulture, Terumo, TetraLogic Pharmaceuticals, Tetraphase Pharmaceuticals, Teva Pharmaceutical Industries, Texas AgriLife Research, Texas Biomedical Research Institute, Texas Children’s Hospital, Texcell, TFS International, The International AIDS Vaccine Initiative, The Medicines Company, Themis Bioscience, Theraclone Sciences, Theradiag, Theranostica, TheraSource, Theratechnologies, Theravance Biopharma, Thermo Fisher Scientific, Thomas Jefferson University, Thorne Research, Tianjin CanSino Biotechnology, Tianjin University, TiGenix, Tika Diagnostics, Titan Pharmaceuticals, Todos Medical, TomegaVax, TONIX Pharmaceuticals, Toulouse University Hospital, TransChem, Translate Bio, Trek Therapeutics, Trellis Bioscience, Trianni, TriLink BioTechnologies, Tripex Pharmaceuticals, Tru-D SmartUVC, True North Laboratory, Truffle Capital, Tsinghua University, TSRL, Tulane University, Turing Pharmaceuticals, Twist Bioscience, Tyber Medical, Tzamal Medical, U.K. Department for International Development, Ubiquigent, Ubiquitome, UgenTec, UK Government, Uldic Investment, UMN Pharma, UNITAID, United Nations Children Fund, United States Agency for International Development, Universite catholique de Louvain, University City Science Center, University College London, University Health Network, University Hospital Bonn, University Hospital Heidelberg, University Hospitals Case Medical Center, University of Alabama, University of Alabama at Birmingham, University of Alberta, University of Buffalo, University of California, Davis, University of California, San Diego, University of California Berkeley, University of California Los Angeles, University of California San Francisco, University of Chicago, University of Colorado, University of Connecticut, University of Dundee, University of Edinburgh, University of Georgia, University of Guelph, University of Hawaii, University of Hong Kong, University of Houston, University of Iowa, University Of Jyvaskyla, University of Kansas, University of Kentucky, University of KwaZulu-Natal, University of Leipzig, University of Liverpool, University of Maryland, University of Maryland Baltimore, University of Maryland School of Medicine, University of Massachusetts, University of Massachusetts Medical School, University of Melbourne, University of Miami, University of Miami Miller School of Medicine, University of Minnesota, University of Missouri, University of Montreal, University of Nagasaki, University of Nebraska, University of New South Wales, University of Notre of Dame, University of Oxford, University of Pennsylvania, University of Pittsburgh, University of Queensland, University of Rochester, University of Sao Paulo, University of Southampton, University of Technology Sydney, University of Texas, University of Texas Medical Branch, University of the Witwatersrand, University of Tokyo, University of Toronto, University of Tubingen, University of Vermont, University of Virginia, University of Washington, University of Western Sydney, University of Wisconsin, University of Wisconsin-Madison, University of Zagreb, University of Zurich, US Army, US Army Medical Research and Material Command, US Army Medical Research Institute of Chemical Defense, US Army Medical Research Institute of Infectious Diseases, US Department of Agriculture, US Government, Ushio, UTILITY Therapeutics, Utrecht University, UV Partners, Vaccitech, Valbiotis, Valeant Pharmaceuticals, Valera Pharmaceutical, Valneva, Vanderbilt University, Vaxart, Vaxeal, Vaxess Technologies, Vaxil BioTherapeutics, VaxNewMo, VBI Vaccines, Vedanta Biosciences, VenatoRx, Ventec Life Systems, Venus Remedies, Verax Biomedical, Vernalis, Versar, Vertex Pharmaceuticals, Vetoquinol, Viamet Pharmaceuticals, Vibalogics, Vical, Vidscrip, ViiV Healthcare, Vikor Scientific, Vinamedical, ViraCor Laboratories, Viracta Therapeutics, ViraCyte, Viral Hemorrhagic Fever Consortium, Virbac, Vir Biotechnology, Viriom, Viroclinics Biosciences, Virox Technologies, VirPath, VisionQuest Biomedical, Visterra, Vitro, Vivaldi Biosciences, VivaLNK, ViveBio, Vizient, VLP Therapeutics, Volk Optical, Voltron Therapeutics, Vortran Medical, VWR International, Vyera Pharmaceuticals, Walgreens, Walter and Eliza Hall Institute, Walter Reed Army Institute of Research, Warp Drive Bio, Washington University in St Louis, Waterstone Pharmaceutical, WCCT Global, Weill Cornell Medical College, Weizmann Institute, Wellcome Trust, Wellgistics, WellSpring Pharmaceutical, Westmead Institute for Medical Research, Wired Holdings, Wistar Institute, World Health Organization, World Pet Care Products Company, WOUNDCHEK Laboratories, WPD Pharmaceuticals, Wuxi Apptec Laboratory Services, WuXi Biologics, Wuxi STA, X-chem, Xagenic, XBiotech, Xellia Pharmaceuticals, Xencor, Xenetic Biosciences, Xenex, Xerox, Xinhua Healthcare Industry, Xisle Pharma Ventures Trust, Xoma, Yale University, Yecuris, Yiling Wanzhou International Pharmaceuticals, Yisheng Biopharma, ZAI Laboratory, Zalgen Labs, ZeptoMetrix, Zhejiang Hisun Pharmaceutical, Ziopharm Oncology, Zoetis, Zolovax, zuChem, Zuellig Pharma China, Zydus Cadila, Zylera Pharmaceuticals, Zymo Research, Zyomyx
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Collaborative R&D
• Contract service
• Equity purchase
• Joint venture
• Royalty financing
• Spin out
• Sub license
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.